[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"kidney-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:kidney-neoplasm":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,45,73,102,135,163,184],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100623513","phase-2-pre-neoshift-rcc-neoadjuvant-hif-inhibitor-immunotherapy-in-rcc-100623513",false,"NCT07397611","Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC","PRE-surgical NEOadjuvant Sandwich Immunotherapy With HIF inhibiTion in Renal Cell Carcinoma (PRENEOSHIFT-RCC)","Inclusion Criteria:\n\n* Adult patients age ≥ 18 years.\n* Histologically confirmed diagnosis of ccRCC by a core-needle biopsy. Patients who have not had prior biopsy may undergo screening if they have suspected RCC but can only proceed to registration if ccRCC (any component) is confirmed on the pre-treatment study biopsy.\n* Stage cT2 RCC with grade 4 or sarcomatoid features, ≥cT3 Nx RCC, or cTany N+ RCC disease for which partial or radical nephrectomy is planned. For clinical staging, a kidney MRI is highly preferred over a CT Abdomen.\n* Participants must have measurable disease i.e. a primary renal tumor that can be accurately measured in at least one dimension as ≥10 mm (≥1 cm) with CT scan or MRI. See Section 11 (Measurement of Effect) for the evaluation of measurable disease.\n* Participants must be planned for surgical resection of their primary renal tumor.\n* ECOG performance status of 0-1.\n* Participants must have adequate organ and marrow function, based upon meeting all of the following laboratory criteria within 14 days before first dose of study treatment:\n\n  1. Absolute neutrophil count ≥ 1.0 × 10\\^9\u002FL without granulocyte colony-stimulating factor support within 2 weeks of screening laboratory sample collection.\n  2. Platelet count ≥ 100 × 10\\^9\u002FL without transfusion within 2 weeks of screening laboratory sample collection.\n  3. Hemoglobin ≥ 10.0 g\u002FdL (or 6.2 mmol\u002FL).\n  4. Aspartate transaminase (AST) ≤ 2.5 × upper limit of normal (ULN)\n  5. Alanine aminotransferase (ALT) ≤ 2.5 × ULN.\n  6. Bilirubin ≤ 1.5 × ULN (except participants with Gilbert syndrome who must have total bilirubin \\\u003C 3.0 mg\u002FdL).\n  7. Activated partial thromboplastin time (aPTT) ≤ 1.5 × ULN.\n  8. Ambulatory oxygen saturation \\>92% on room air at time of screening.\n  9. Serum albumin ≥ 2.8 g\u002Fdl.\n  10. INR ≤ 1.5.\n  11. Calculated creatinine clearance ≥ 40 mL\u002Fmin (≥ 0.67 mL\u002Fsec) using the Cockcroft-Gault equation:\n\n      ---Males: (140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72)\n\n      ---Females: \\[(140 - age) x weight (kg)\u002F(serum creatinine \\[mg\u002FdL\\] × 72)\\] × 0.85\n* No exercise-induced desaturation on a 6-minute walk test, defined as a blood oxygen saturation by pulse oximetry ≤ 88%.\n* No active clinical pneumonitis at screening.\n* No medical history of severe chronic obstructive pulmonary disease (COPD)\n* Screening echocardiogram or MUGA scan must demonstrate a left ventricular ejection fraction (LVEF) greater than the institutional lower limit of normal (LLN).\n* Negative serum pregnancy test at screening for women of childbearing potential. Female subjects are considered to be of childbearing potential unless one of the following criteria is met: permanent sterilization (hysterectomy, bilateral salpingectomy, or bilateral oophorectomy) or documented postmenopausal status (defined as 12 months of amenorrhea in a woman \\> 45 years-of-age in the absence of other biological or physiological causes. In addition, females \\\u003C 55 years-of-age must have a serum follicle stimulating hormone \\[FSH\\] level \\> 40 mIU\u002FmL to confirm menopause). Note: Documentation may include review of medical records, medical examination, or medical history interview by study site staff.\n* Sexually active fertile subjects and their partners must agree to use highly effective methods of contraception during the course of the study and for the following durations after the last dose of treatment (whichever is later). An additional contraceptive method, such as a barrier method (eg, condom), is required. In addition, men must agree not to donate sperm and women must agree not to donate eggs (ova, oocyte) for the purpose of reproduction during these same periods. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately.\n* Through 7 days after the last dose of casdatifan and 120 days after the last dose of zimberelimab for women of childbearing potential and for men\n* Ability to understand and the willingness to sign a written informed consent document.\n* Ability to swallow tablets.\n\nExclusion Criteria:\n\n* Any prior systemic therapy for treatment of renal cell carcinoma.\n* Any radiation therapy within 4 weeks before the first dose of study treatment.\n* Any clear evidence of distant metastases. Enlarged lymph nodes that are planned to be removed during nephrectomy are permitted.\n* Clinical pneumonitis or concern for inflammatory lung disease at time of screening.\n* Any complementary medications (eg, herbal supplements or traditional Chinese medicines) with the intention to treat the disease under study within 2 weeks before first dose of study treatment.\n* Other prior malignancy active within the previous year except for locally curable cancers (\\>90%) that have been apparently cured, such as basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix, breast, or Gleason 6 prostate cancer. Also, indolent malignancies, including but not limited to early-stage chronic lymphocytic leukemia and follicular lymphoma, that don't require anti-cancer treatment, could be allowed after discussion with the medical monitor.\n* QTc ≥ 480 msec using Fridericia's correction (QTcF) (based on an average of triplicate recordings).\n* Malabsorption condition that would alter the absorption of orally administered medications.\n* Patient has had any major cardiovascular event within 6 months prior to study drug administration including but not limited to myocardial infarction, unstable angina, cerebrovascular accident, transient ischemic event, pulmonary embolism, clinically significant ventricular arrhythmias (eg, sustained ventricular tachycardia, ventricular fibrillation, torsades de pointes) or New York Heart Association Class III or IV heart failure.\n* The subject has uncontrolled, significant intercurrent or recent illness including, but not limited to, the following conditions:\n\n  a. Cardiovascular disorders: i. Congestive heart failure New York Heart Association Class 2 or greater, unstable angina pectoris, serious cardiac arrhythmias (eg, ventricular flutter, ventricular fibrillation, Torsades de pointes).\n\nii. Uncontrolled hypertension defined as sustained blood pressure (BP) \\> 150 mm Hg systolic or \\> 95 mm Hg diastolic despite optimal antihypertensive treatment.\n\niii. Any history of stroke (including transient ischemic attack \\[TIA\\]), myocardial infarction, or other clinically significant ischemic event within 12 months before first dose of study treatment.\n\niv. Clinically significant pulmonary embolism (PE) or deep vein thrombosis (DVT) or prior clinically significant venous or non-CVA\u002FTIA arterial thromboembolic events within 3 months before to first dose of study treatment. Thrombus felt due to tumor and not a bland thrombus is permitted.\n\nNote: Subjects with a diagnosis of DVT\u002FPE due to bland thrombus need to be asymptomatic and have at least 4 weeks of anticoagulation before first dose of study treatment.\n\nv. Any history of myocarditis.\n\nb. Gastrointestinal (GI) disorders including those associated with a high risk of perforation or fistula formation: i. Tumors invading the GI-tract from external viscera. ii. Active and symptomatic peptic ulcer disease, inflammatory bowel disease, diverticulitis, cholecystitis, symptomatic cholangitis or appendicitis, or acute pancreatitis.\n\niii. Acute obstruction of the bowel, gastric outlet, or pancreatic or biliary duct within 6 months unless the cause of obstruction is definitively managed and subject is asymptomatic.\n\niv. Abdominal fistula, gastrointestinal perforation, bowel obstruction, or intra-abdominal abscess within 6 months before the first dose. Note: Complete healing of an intra-abdominal abscess must be confirmed before the first dose of study treatment.\n\nv. Known gastric or esophageal varices. vi. Ascites requiring drainage within 28 days prior to initiation of protocol therapy c. Autoimmune disease that has been symptomatic or required treatment with 1mg\u002Fkg of corticosteroids within the past two years from the date of randomization. Diabetes mellitus and thyroid auto-immune diseases are excluded.\n\nd. Any condition requiring systemic treatment with either corticosteroids (\\> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of randomization. Note: Inhaled, intranasal, intra-articular, or topical steroids are permitted. Adrenal replacement steroid doses \\> 10 mg daily prednisone equivalent are permitted. Transient short-term use of systemic corticosteroids for allergic conditions (eg, contrast allergy) is also allowed. Corticosteroids given as short course premedication is acceptable.\n\n* Other clinically significant disorders that would preclude safe study participation.\n\n  1. Active infection requiring systemic treatment. Note: Prophylactic antibiotic treatment is allowed.\n  2. Infection with acute or chronic hepatitis B or C with detectable viral load, human immunodeficiency virus (HIV) infection with detectable viral load or acquired immunodeficiency syndrome (AIDS)-related illness.\n  3. Serious non-healing wound\u002Fulcer\u002Fbone fracture. Note: non-healing wounds or ulcers are permitted if due to tumor-associated skin lesions.\n  4. Pharmacologically uncompensated, symptomatic hypothyroidism.\n  5. Moderate to severe hepatic impairment (Child-Pugh B or C).\n  6. History of solid organ or allogeneic stem cell transplant.\n* Major surgery (as defined in Appendix B) within 4 weeks prior to first dose of study treatment. Minor surgery (eg, simple excision, tooth extraction) within 7 days before the first dose of study treatment. Complete wound healing from major or minor surgery must have occurred at least prior to the first dose of study treatment.\n* Patients who are receiving treatment with strong CYP3A4 inhibitors and inducers should have a washout period of 28 days or 5 half-lives of the concerning medicine prior to starting casdatifan.\n* History of psychiatric illness, mental condition or substance use disorders that are likely to interfere with ability to comply with protocol requirements or give informed consent.\n* Use of any live vaccines against infectious diseases within 28 days of first dose of study drug.\n* Current breastfeeding.\n* Previously identified allergy or hypersensitivity to components of the study treatment formulations.\n* Any use of supplemental or intermittent oxygen therapy.\n* Other conditions, which in the opinion of the Investigator, would compromise the safety of the patient or the patient's ability to complete the study.","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","The purpose of this study is to see whether the drug casdatifan is safe and effective either by itself or in combination with the drug zimberelimab in participants with resectable clear cell renal cell carcinoma (ccRCC).\n\nThe names of the study drugs involved in this study are:\n\n* Casdatifan (a type of HIF-2α inhibitor)\n* Zimberelimab (a type of monoclonal antibody)",[26,27,28,29],"Renal Cell Carcinoma","Kidney Cancer","Kidney Neoplasm","Renal Carcinoma",[26,27,28,29,31],"ccRCC","RECRUITING","2026-03-18",{"date":35,"type":36},"2026-03-20","ACTUAL",{"date":38,"type":36},"2026-03-09",{"date":40,"type":20},"2029-09-30",{"name":42,"class":43},"Dana-Farber Cancer Institute","OTHER",3,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":54,"targetDuration":56,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100235711","the-delayed-intervention-and-surveillance-for-small-renal-masses-dissrm-registry-100235711","NCT02346435","The Delayed Intervention and Surveillance for Small Renal Masses (DISSRM) Registry","DISSRM","Inclusion Criteria:\n\n* Must have a solid, enhancing renal mass ≤4cm at its greatest dimension found on incidental scanning in the last 6 months.\n* Age ≥ 18 and able to read, understand and sign informed consent.\n* Must be willing to adhere to the treatment algorithm and time constraints therein.\n\nExclusion Criteria:\n\n* Cannot have suspicion of metastases to the kidney if any other malignancy diagnosed within two years of study entry.",true,"100 Years",{"count":55,"type":20},600,"5 Years","OBSERVATIONAL","Retrospective studies indicate that active surveillance for clinically localized, small renal masses (cT1a, \\\u003C=4cm) is safe. It is our hypothesis that active surveillance is safe and efficacious when compared prospectively to patients undergoing immediate intervention for their small renal mass.",[28],[61,62],"small renal mass","active surveillance","2026-03-04",{"date":65,"type":36},"2026-03-05",{"date":67,"type":4},"2009-01",{"date":69,"type":20},"2028-01",{"name":71,"class":43},"Abramson Cancer Center at Penn Medicine",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":87,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":93,"lastUpdatePostDateStruct":94,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":72},"100610963","clinical-trial-addressing-the-best-surgical-approach-for-partial-nephrectomy-with-single-port-robotic-system-in-the-management-of-localized-renal-cell-carcinoma-100610963","NCT07234409","Clinical Trial Addressing the Best Surgical Approach for Partial Nephrectomy With Single Port Robotic System in the Management of Localized Renal Cell Carcinoma","Standard Flank Approach vs Supine Approach for Robot-assisted Partial Nephrectomy","K3","* Age ≥ 18 years;\n* Presence of a single, unilateral, primary renal mass ≤ 7 cm in diameter (clinical stage cT1) documented CT scan\n* No evidence of systemic disease or lymph node involvement;\n* Candidate for robot-assisted partial nephrectomy using the Da Vinci SP platform;\n* Signed informed consent\n* Absence of solitary kidney status\n* No previous partial nephrectomy\u002Fies on the same kidney\n* Absence of preoperative chronic kidney disease (CKD) stage 5\n* Absence of any condition that makes mandatory or significantly more adequate the choice of a specific approach over the others (e.g., multiple previous major abdominal surgeries, horseshoe kidney, presence of stomas)",{"count":82,"type":20},124,[84],"NA","This study aims to find out which surgical position is safer and works better for patients candidate to robot-assisted partial nephrectomy (RAPN) - a minimally invasive procedure to remove a small kidney tumor while preserving healthy kidney tissue.\n\nDuring this operation, the patient can be placed in two different positions:\n\n* the standard flank position, where the patient lies on their side\n* a newer supine position, where the patient lies on their back using a technique called Supine Anterior Retroperitoneal Approach (SARA).\n\nBoth approaches are performed using the Da Vinci® Single Port (SP) robotic system, a state-of-the-art surgical robot that allows the operation to be done through a single small incision.\n\nThe traditional flank position has been used for many years, but it can be uncomfortable for patients and may increase the risk of certain anesthetic or nerve-related complications, especially in people with higher body weight. The new supine SARA technique could make surgery faster, safer, and less painful, but it has not yet been tested in a randomized study.\n\nThis is the first clinical trial designed to directly compare these two approaches in patients with small and localized kidney cancers (tumors ≤7 cm, stage cT1).\n\nThe study will include 124 patients treated at ASST Grande Ospedale Metropolitano Niguarda in Milan, Italy - a leading center in robotic urologic surgery.",[28],[88,89,90,91,92],"kidney cancer","robotic surgery","single port","supine position","full flank position","2025-11-18",{"date":95,"type":36},"2025-11-21",{"date":97,"type":36},"2025-10-10",{"date":99,"type":20},"2027-03-30",{"name":101,"class":43},"Niguarda Hospital",{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":72},"100585511","phase-4-primary-tumor-ablation-and-outcome-in-metastatic-renal-cell-carcinoma-treated-with-immunotherapy-combinations-100585511","NCT06903312","Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.","Clinical and Humoral Impact of Primary Tumor Ablation in Metastatic Renal Cell Carcinoma Treated With Immunotherapy. The ITALIC-RCC Randomized Study.","ITALIC-RCC","Inclusion Criteria:\n\n1. Informed consent obtained before any study-specific procedures. Patients must be able to understand and be willing to sign a written informed consent.\n2. Male or female patient ≥18 years of age.\n3. Histological or cytological documentation of renal cell carcinoma with predominantly clear cell histology.\n4. Evidence of primary renal cancer.\n5. Measurable or not measurable metastatic disease according to Response Evaluation Criteria in Solid Tumors criteria, version 1.1 \\[22\\].\n6. Eastern Cooperative Oncology Group performance status of ≤1.\n7. Life expectancy of at least 9 months.\n8. Under treatment with one anti-PD1 based therapy (SOC) among axitinib + pembrolizumab or cabozantinib + nivolumab or lenvatinib + pembrolizumab or nivolumab alone after nivolumab + ipilimumab for at least 24 but not more than 52 weeks at the time of the signed informed consent and without evidence of progressive disease based on RECIST criteria v 1.1 \\[21\\].\n9. Eligible to continue the combination of therapies for mRCC (or nivolumab alone in case of nivolumab + ipilimumab).\n10. Women of childbearing potential and men must agree to use adequate contraception since signing of the informed consent form until at least 3 months after the last study drug administration. The investigator or a designated associate is requested to advise the subject how to achieve an adequate birth control. Adequate contraception is defined in the study as any medically recommend method (or combination of methods) as per standard of care.\n11. Adequate bone-marrow, liver, and renal function as assessed by the following laboratory requirements conducted within 7 days of starting to study treatment:\n\n    1. Creatinine value \\\u003C2.5 mg\u002Fdl and creatinine clearance \\> 30 ml\u002Fmin evaluated by the Cockcroft-Gault Formula.\n    2. Total bilirubin ≤1∙5 × the upper limit of normal (ULN);\n    3. Alanine aminotransferase and aspartate aminotransferase ≤2 × ULN (≤5 × ULN for patients with liver involvement of their cancer);\n    4. International normalized ratio (INR) and partial thromboplastin time (PTT) ≤1∙5 × ULN. Subjects who are therapeutically treated with an agent such as warfarin or heparin will be allowed to participate if no prior evidence of an underlying abnormality in coagulation parameters exists. Close monitoring of at least weekly evaluations will be performed until INR and PTT are stable based on a pre-dose measurement as defined by the local standard of care;\n    5. Platelet count ≥100 000\u002Fmm3, hemoglobin \\>9 g\u002Fdl, absolute neutrophil count \\>1,500\u002Fmm3;\n    6. Alkaline phosphatase limit ≤2∙5 × ULN (≤5 × ULN for patients with liver involvement of their cancer).\n\nExclusion Criteria:\n\n1. More than one treatment for metastatic or locally advanced renal cell carcinoma.\n2. Solitary kidney\n3. Any contraindication to surgery or radiotherapy on primary renal tumor.\n4. Discontinuation (definitive) of one of the therapies for mRCC due to toxicity (previous discontinuation of ipilimumab in the ipilimumab + nivolumab combo is allowed).\n5. Concurrent or previous cancer within 3 years before enrolment EXCEPT curatively treated cervical cancer in situ, non-melanoma skin cancer and pT2 prostate cancer with PSA\\\u003C0.01 or non-muscle invasive bladder cancer.\n6. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days before the signed informed consent.\n7. Pregnancy or breast-feeding. Women of childbearing potential must have a pregnancy test performed a maximum of 7 days before surgery or radiotherapy on primary tumor, and a negative result must be documented before start of treatment.\n8. Any cardiological condition among:\n\n   1. Congestive heart failure of New York Heart Association class 3 or worse.\n   2. Unstable angina (angina symptoms at rest), new-onset angina (begun within the last 3 months). Myocardial infarction less than 6 months before start of study drug.\n   3. Cardiac arrhythmias requiring anti-arrhythmic therapy (beta-blockers or digoxin are permitted).\n   4. Uncontrolled hypertension (systolic blood pressure \\>150 mmHg or diastolic pressure \\>90 mmHg despite optimal medical management).\n   5. Arterial or venous thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), pulmonary embolism within the 4 months before start of study.\n9. Ongoing infection higher than National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 6.0 grade 2.\n10. Known history of human immunodeficiency (HIV) virus infection or known history of chronic hepatitis B or C.\n11. Any autoimmune reaction or toxicity that contraindicates the use of anti-PD1 therapy.\n12. Seizure disorder requiring medication.\n13. Symptomatic metastatic brain or meningeal tumors unless the patient is \\>2 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also, the patient must not be undergoing acute steroid therapy or tapering (chronic steroid therapy is acceptable provided that the dose is stable for 1 month before and after screening radiographic studies).\n14. History of organ allograft.\n15. Evidence or history of bleeding diathesis. Any hemorrhage or bleeding event of CTCAE grade 3 or higher within 4 weeks of start of study medication.\n16. Non-healing wound, ulcer, or bone fracture.\n17. Renal failure requiring hemodialysis or peritoneal dialysis.\n18. Any illness or medical conditions that are unstable or could jeopardize the safety of the patient and his or her compliance in the study.",{"count":111,"type":20},409,[113],"PHASE4","This is Phase IV, randomized, multi arm, multicenter, low interventional clinical trial, aiming to evaluate if treatment of primary tumor in mRCC patients with initial benefit to anti-PD1- based therapy (SOC) can improve the overall survival.\n\nAll patients eligible according to inclusion and exclusion criteria will be enrolled and randomized to different treatment options based on tumor extension of the primary kidney cancer.\n\nThose with primary kidney cancer ≤ 4 cm will be randomized 1:1:1 to receive:\n\n* Cytoreductive Nephrectomy + standard of care (SOC) or\n* RT on primary tumor + SOC or SOC alone.\n\nThose with primary kidney cancer \\> 4 cm will be randomized 1:1 to receive:\n\n• Deferred Cytoreductive Nephrectomy + SOC or SOC alone. Patients randomized to Deferred Cytoreductive Nephrectomy can be treated with one among radical nephrectomy; partial nephrectomy or lumpectomy.\n\nPatients randomized to RT should be treated with single shot of 25 Gy (or with multiple fractions with equivalent biological dose).\n\nThe SOC medical therapy is the continuation of the combination of medical therapy for mRCC including one of the available combination among axitinib + pembrolizumab or cabozantinib + nivolumab or lenvatinib + pembrolizumab or nivolumab alone after nivolumab + ipilimumab.",[116,28,117,27,118,119],"Renal Cell Cancer","Immunotherapy","Surgery Programmed","Radiotherapy",[121,122,123,124,125],"renal cancer","primary tumor","cytoreductive nephrectomy","immunothreapy","radiotherapy","2025-06-30",{"date":128,"type":36},"2025-07-03",{"date":130,"type":36},"2025-06-15",{"date":132,"type":20},"2028-04-01",{"name":134,"class":43},"Fondazione Policlinico Universitario Agostino Gemelli IRCCS",{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":141,"eligibilityCriteria":142,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":143,"targetDuration":4,"studyType":21,"phases":145,"briefSummary":146,"conditions":147,"keywords":148,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100425741","impact-of-chronic-renal-failure-on-plasma-exposure-of-kinase-inhibitors-in-patients-treated-for-metastatic-kidney-cancer-100425741","NCT04823923","Impact of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors in Patients Treated for Metastatic Kidney Cancer","Study of the Impact of the Stage of Chronic Renal Failure on Plasma Exposure of Kinase Inhibitors (ITK) in Patients Treated for Metastatic Kidney Cancer","IREKI","Inclusion Criteria:\n\n1. Patient followed for metastatic clear cell renal cell carcinoma.\n2. Age ≥18 years old.\n3. Performance Status (PS) according to Eastern Cooperative Oncology Group (ECOG) = 0, 1 or 2\n4. Patient treated with a VEGF-R inhibitor: pazopanib or cabozantinib for metastatic kidney cancer.\n5. If patient doesn't have renal failure -\\> group 1, or if patient has chronic renal failure according to the moderate stage Chronic Kidney Disease - Epidemiology (CKD-EPI) formula (Clr \\\u003C60 ml \u002F min, stage 3) -\\> group 2, or if patient have chronic renal failure according to the CKD-EPI formula of severe or terminal stage (Clr \\\u003C30 ml \u002F min, stage 4 and stage 5), with or without dialysis -\\> group 3.\n6. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.\n7. Patient having given informed, written and express consent.\n8. Affiliation to the French Social Security System.\n\nExclusion Criteria:\n\n1. Indication other than clear cell renal cell carcinoma for these same ITKs\n2. Pregnant or breast-feeding subjects\n3. Patient whose regular follow-up is impossible for psychological, family, social or geographic reasons,\n4. Patient under guardianship, curatorship or safeguard of justice\n5. Participation in another clinical study with a research product during the last 30 days before inclusion.",{"count":144,"type":20},60,[84],"The study of the blood concentration of ITK what are pazopanib and cabozantinib at 1 month and 3 months from the start of treatment will allow to evaluate the impact of renal failure on their efficacy and toxicity in patients with metastatic kidney cancer.",[28],[149,150,151,152],"metastatic kidney cancer","pazopanib","cabozantinib","renal failure","2025-02-11",{"date":155,"type":36},"2025-02-12",{"date":157,"type":36},"2021-12-06",{"date":159,"type":20},"2026-03",{"name":161,"class":43},"Institut du Cancer de Montpellier - Val d'Aurelle",5,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":53,"enrollmentInfo":170,"targetDuration":172,"studyType":57,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":175,"lastUpdatePostDateStruct":176,"startDateStruct":178,"completionDateStruct":180,"leadSponsor":182,"locationsCount":162},"100414828","german-national-registry-for-nss-100414828","NCT04681690","German National Registry for NSS","German National Registry for Nephron-Sparing Surgery","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Written informed consent\n* Localized renal parenchymal mass amenable to nephron-sparing surgery\n* Adequate imaging of the abdomen (CT or MR with contrast)\n\nExclusion Criteria:\n\n* Patient with (or suspected to have) urothelial cancer of the kidney\n* Prior nephron-sparing surgery on ipsilateral kidney\n* metastasized renal cell carcinoma",{"count":171,"type":20},1000,"60 Months","The G-NeSS Registry prospectively collects data on clinical and outcome variables from patients undergoing partial nephrectomy for renal masses. Analyses of data aims at identifying key factors determining the quality of surgical care in this patient population.",[28],"2025-01-27",{"date":177,"type":36},"2025-01-29",{"date":179,"type":36},"2020-12-15",{"date":181,"type":20},"2027-09-15",{"name":183,"class":43},"Association of Urologic Oncology (AUO)",{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":190,"eligibilityCriteria":191,"healthyVolunteers":11,"sex":16,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":21,"phases":196,"briefSummary":198,"conditions":199,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":72},"100551977","phase-3-systemic-treatment-alone-versus-systemic-treatment-plus-radiotherapy-in-oligometastatic-renal-cell-carcinoma-100551977","NCT06467097","Systemic Treatment Alone Versus Systemic Treatment Plus Radiotherapy in Oligometastatic Renal Cell Carcinoma","A Phase Ⅲ Randomized Study Systemic Treatment Alone Versus Systemic Treatment Plus Stereotactic Abative Body Radiotherapy for Patients With Oligometastatic Renal Cell Carcinoma: SABLOR Study","SABLOR","Inclusion Criteria:\n\n1. Patients with metastatic renal cell carcinoma classified within the ESTRO\u002FEORTC classification system as having ≤ 5 metastases, ≤ 3 metastatic organs, and meeting criteria for new, recurrent, or induced metastases.\n2. Patients aged 20 to 80 years.\n3. Patients with individual metastases ≤ 5 cm in longest diameter.\n4. Patients with primary tumors surgically removed or scheduled for surgery.\n5. Patients histologically diagnosed with clear cell carcinoma.\n6. Patients with ECOG performance status 0-1.\n7. Patients with normal major organ function and bone marrow function meeting specific criteria: WBC ≥ 2,000\u002FμL, neutrophils ≥ 1,000\u002FμL, platelets ≥ 50,000\u002FμL.\n8. Patients who understand the contents of the informed consent form, voluntarily consent to participate in the study, and sign the informed consent form.\n9. Patients who agree to use contraception from the time of signing the consent form until 1 year after the last standard systemic therapy.\n10. Breastfeeding women who agree to stop breastfeeding for at least 5 months after the last standard systemic therapy.\n11. Patients with visible tumors outside the scope of tumor removal surgery (surgical therapy) for metastatic lesions.\n\nExclusion Criteria:\n\n1. Patients with total bilirubin \\> 3.6 mg\u002FdL.\n2. Patients with AST \\>160 U\u002FL, ALT \\> 165 U\u002FL.\n3. Patients unable to maintain position for partial nephrectomy radiotherapy.\n4. Patients with a history of radiotherapy to metastatic renal cell carcinoma or surrounding areas.\n5. Patients with confirmed brain, peritoneal, or pleural metastases.\n6. Patients diagnosed with another solid tumor and treated within 2 years or with residual lesions.\n7. Patients who do not consent to participate in the study.\n8. Pregnant patients.","20 Years","80 Years",{"count":195,"type":20},88,[197],"PHASE3","To evaluate whether incorporating locoregional radiotherapy in the treatment of oligometastatic renal cell carcinoma, including inductive oligometastases, along with standard systemic therapy, contributes to improved progression-free survival rates for patients.",[28],"2024-06-18",{"date":202,"type":36},"2024-06-20",{"date":204,"type":36},"2024-04-16",{"date":206,"type":20},"2031-02-13",{"name":208,"class":43},"Samsung Medical Center"]